Trial Profile
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Pembrolizumab (Primary) ; Tisotumab-vedotin (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms innovaTV 207
- Sponsors Seagen
- 01 Dec 2023 Planned primary completion date changed from 30 Nov 2023 to 30 Apr 2025.
- 26 Jun 2023 Planned number of patients changed from 532 to 692.
- 26 Jun 2023 Planned End Date changed from 31 Dec 2024 to 30 Nov 2026.